

Notice of change of interests of substantial holder

To Company Name/Scheme Actinogen Medical Limited

ACN/ARSN 086 778 476

1. Details of substantial holder (1)

Name BVF Partners L.P. on its own behalf and on behalf of BVF Inc. and Mark N. Lampert

ACN/ARSN (if applicable) _____

There was a change in the interests of the substantial holder on

12/11/2024, 13/11/2024, 14/11/2024, 15/11/2024, 18/11/2024, 19/11/2024, 20/11/2024, 21/11/2024, 22/11/2024, 25/11/2024, 26/11/2024, 27/11/2024, 28/11/2024, 29/11/2024, 2/12/2024, 3/12/2024, 4/12/2024, 16/12/2024*
(*On 16/12/2024, there was a dilution of % interest as a result of the issuance by Actinogen Medical Limited of 59,500,000 shares to persons other than the substantial holders and relevant interest holders in this form. That share issuance resulted in the need to give this Form 604. The substantial holders and relevant interest holders named in this form did not acquire or dispose of any shares on 16/12/2024.)

The previous notice was given to the company 26/09/2024

The previous notice was dated 26/09/2024

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Fully Paid Ordinary Shares	247,334,680	8.40%	228,334,680	7.29%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
12/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$16,330.93	702,303 fully paid ordinary shares	702,303
13/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$11,068.07	473,985 fully paid ordinary shares	473,985
13/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$197.33	8,450 fully paid ordinary shares	8,450
14/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$39,569.11	1,631,622 fully paid ordinary shares	1,631,622

14/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$13,826.88	570,189 fully paid ordinary shares	570,189
15/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$29,649.67	1,275,068 fully paid ordinary shares	1,275,068
15/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$11,432.70	491,700 fully paid ordinary shares	491,700
18/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$9,221.02	393,170 fully paid ordinary shares	393,170
18/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$3,458.41	147,504 fully paid ordinary shares	147,504
19/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$2,071.94	86,504 fully paid ordinary shares	86,504
19/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$745.25	31,156 fully paid ordinary shares	31,156
20/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$62,878.90	2,451,553 fully paid ordinary shares	2,451,553
20/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P.	On Market sale of fully paid ordinary shares	\$35,357.21	1,378,524 fully paid ordinary shares	1,378,524
20/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$30,147.11	1,175,390 fully paid ordinary shares	1,175,390
20/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$12,640.73	492,882 fully paid ordinary shares	492,882
21/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$14,706.47	573,383 fully paid ordinary shares	573,383
21/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P.	On Market sale of fully paid ordinary shares	\$12,322.82	480,448 fully paid ordinary shares	480,448
21/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$1,726.13	67,338 fully paid ordinary shares	67,338
21/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$1,443.43	56,277 fully paid ordinary shares	56,277
22/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P.	On Market sale of fully paid ordinary shares	\$1,371.38	54,746 fully paid ordinary shares	54,746
22/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$1,294.37	51,672 fully paid ordinary shares	51,672

22/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$140.40	5,605 fully paid ordinary shares	5,605
22/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$79.91	3,230 fully paid ordinary shares	3,230
25/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$14,671.98	607,495 fully paid ordinary shares	607,495
25/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$11,932.70	494,075 fully paid ordinary shares	494,075
25/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$1,290.66	53,440 fully paid ordinary shares	53,440
25/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$505.31	20,964 fully paid ordinary shares	20,964
26/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$30,993.20	1,257,300 fully paid ordinary shares	1,257,300
26/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$24,868.68	1,008,847 fully paid ordinary shares	1,008,847
26/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$2,821.29	114,451 fully paid ordinary shares	114,451
26/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$1,060.87	43,077 fully paid ordinary shares	43,077
27/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$8,273.42	334,274 fully paid ordinary shares	334,274
27/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$7,277.74	294,045 fully paid ordinary shares	294,045
27/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$197.50	7,980 fully paid ordinary shares	7,980
27/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$2.36	0,136 fully paid ordinary shares	136
28/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$4,590.23	183,977 fully paid ordinary shares	183,977
28/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$4,359.09	174,713 fully paid ordinary shares	174,713
28/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$132.06	5,293 fully paid ordinary shares	5,293

29/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$6,952.44	279,774 fully paid ordinary shares	279,774
29/11/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P.	On Market sale of fully paid ordinary shares	\$6,373.41	256,473 fully paid ordinary shares	256,473
29/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$324.44	13,056 fully paid ordinary shares	13,056
29/11/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$10.41	0,459 fully paid ordinary shares	459
2/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$8,787.98	342,630 fully paid ordinary shares	342,630
2/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P.	On Market sale of fully paid ordinary shares	\$7,878.14	307,157 fully paid ordinary shares	307,157
2/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$499.33	19,468 fully paid ordinary shares	19,468
2/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$72.51	2,866 fully paid ordinary shares	2,866
3/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$5,808.92	219,644 fully paid ordinary shares	219,644
3/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P.	On Market sale of fully paid ordinary shares	\$5,146.61	194,601 fully paid ordinary shares	194,601
3/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$986.45	37,337 fully paid ordinary shares	37,337
3/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$921.78	34,854 fully paid ordinary shares	34,854
4/12/2024	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$1,242.22	47,508 fully paid ordinary shares	47,508
4/12/2024	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P.	On Market sale of fully paid ordinary shares	\$1,082.69	41,407 fully paid ordinary shares	41,407

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
BVF Partners, L.P.	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd	Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below.	Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities.	228,334,680 fully paid ordinary shares	228,334,680
BVF Inc. and Mark N. Lampert	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd	Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below.	Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P.	228,334,680 fully paid ordinary shares	228,334,680
BVF Partners OS Ltd.	HSBC Custody Nominees (Australia) Limited	BVF Partners OS Ltd.	Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities.	11,928,027 fully paid ordinary shares	11,928,027
Biotechnology Value Trading Fund OS, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Trading Fund OS, L.P.	Relevant interest arises under section 608(1)(a) of the Corporations Act as holder of the securities	11,928,027 fully paid ordinary shares	11,928,027
BVF I GP LLC	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund, L.P.	Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF I GP LLC acting as general partner of Biotechnology Value Fund, L.P., whereby it holds the authority to cast votes in respect of the securities.	117,375,080 fully paid ordinary shares	117,375,080
Biotechnology Value Fund, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund, L.P.	Relevant interest arises under sections 608(1)(b) and 608(1)(c) of the Corporations Act as beneficial holder of the securities	117,375,080 fully paid ordinary shares	117,375,080
BVF II GP LLC	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund II, L.P.	Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF II GP LLC acting as general partner of Biotechnology Value Fund II, L.P., whereby it holds the authority to cast votes in respect of the securities.	94,555,970 fully paid ordinary shares	94,555,970
Biotechnology Value Fund II, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund II, L.P.	Relevant interest arises under sections 608(1)(b) and 608(1)(c) of the Corporations Act as beneficial holder of the securities	94,555,970 fully paid ordinary shares	94,555,970
MSI BVF SPV, LLC	BNP Paribas Nominees Pty Ltd	MSI BVF SPV, LLC	Relevant interest arises under section 608(1)(a) of the Corporations Act as holder of the securities	4,475,603 fully paid ordinary shares	4,475,603

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Not applicable	Not applicable

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
BVF Partners L.P. BVF I GP LLC BVF II GP LLC Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc.	44 Montgomery Street, 40 th Floor San Francisco, California 94104 United States of America
BVF Partners OS, Ltd Biotechnology Value Trading Fund OS, L.P.	PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
MSI BVF SPV, LLC	c/o Magnitude Capital, L.L.C. 200 Park Avenue, 56 th Floor New York, NY 10166
Mark N. Lampert	c/o BVF Inc 44 Montgomery Street, 40 th Floor San Francisco, California 94104 United States of America

Signature

print name Mark Lampert on behalf of himself, BVF Partners L.P., and BVF Inc.

capacity Director and Officer of
the Substantial Holders

sign here



date 18/12/2024